Over the past few years, GLP-1 medications such as Ozempic® (semaglutide) and Mounjaro® (tirzepatide) have transformed the weight-management landscape. Patients often see dramatic improvements in appetite control and early weight loss. But here’s the challenge many physicians and patients quietly admit: 👉 What happens when the prescription ends—or when weight plateaus despite continued use? The Evidence We Need to Pay Attention To A 2022 study published in Diabetes, Obesity